Page 1/20 A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer Ilya Tsimafeyeu (  tsimafeyeu@gmail.com ) Bureau of Cancer Research Galina Statsenko Omsk Regional Cancer Center Liubov Vladimirova National Medical Research Centre for Oncology Natalia Besova N.N. Blokhin National Medical Research Center of Oncology Grigory Raskin Dr. Berezin Medical Institute Ivan Rykov St. Petersburg Clinical Hospital of the Russian Academy of Sciences Anastasia Mochalova Medsi Otradnoe Igor Utyashev Hadassah Medical Moscow Svetlana Gorbacheva Exacte Labs Vasily Kazey Exacte Labs Evgenia Gavrilova Ruspharmtech LLC Nadezhda Dragun Ruspharmtech LLC Vladimir Moiseyenko Clinical and Research Center of Specialized Types of Medical Care (Oncological) Sergei Tjulandin N.N. Blokhin National Medical Research Center of Oncology Elena Artamonova N.N. Blokhin National Medical Research Center of Oncology